Showing results (321-330 of 536) with videos related to
Sort By:
Pageof 54
Archives of Neurology|May 19, 2004
Pituitary volume and headache: size is not everythingMiles J Levy, H Rolf Jäger, Michael Powell, et al.Annals of Neurology|October 31, 2012
Acid-sensing ion channel 1: a novel therapeutic target for migraine with auraPhilip R Holland, Simon Akerman, Anna P Andreou, et al.Headache|March 13, 2018
Transcranial Magnetic Stimulation for Migraine Prevention in Adolescents: A Pilot Open-Label StudySamantha L Irwin, William Qubty, I Elaine Allen, et al.Brain : a Journal of Neurology|March 27, 2020
Structural and functional footprint of visual snow syndromeChristoph J Schankin, Farooq H Maniyar, Denise E Chou, et al.BMC Neurology|December 16, 2014
Enhancing cognitive-behavioural therapy for recurrent headache: design of a randomised controlled trialPaul R Martin, Sharon Mackenzie, Siavash Bandarian-Balooch, et al.Cephalalgia : an International Journal of Headache|March 11, 2015
Is migraine a risk factor for pediatric stroke?Amy A Gelfand, Heather J Fullerton, Alice Jacobson, et al.British Journal of Pharmacology|January 25, 2020
Acid-sensing ion channel 3 blockade inhibits durovascular and nitric oxide-mediated trigeminal painChristopher M Holton, Lauren C Strother, Isaac Dripps, et al.Journal of Patient-Reported Outcomes|December 18, 2024
Impact of eptinezumab on work productivity beyond reductions in monthly migraine days: post hoc analysis of the DELIVER trialPiero Barbanti, Susanne F Awad, Heather Rae-Espinoza, et al.Headache|June 22, 2019
The Association Between Parental Migraine and Infant Colic: A Cross-Sectional, Web-Based, U.S. Survey StudyAmy A Gelfand, Dawn C Buse, Michael D Cabana, et al.The Lancet. Neurology|August 22, 2020
Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trialPeter J Goadsby, David W Dodick, Jessica Ailani, et al.Pageof 54